Company Overview
Zymeworks Inc., a biotechnology company, develops biotherapeutics for the treatment of cancer, inflammation, and autoimmune diseases. The company's platforms include Azymetric multispecific antibody platform; Drug Conjugate platform that includes a suite of proprietary cytotoxins comprising topoisomerase and microtubulin inhibiting toxins, stable linkers, and conjugation technologies; EFECT platform, which consists of a set of modifications to the Fc region of antibodies; and ProTECT, a tumor-specific immune co-stimulation platform. Its lead product candidates include Ziihera (zanidatamab-hrii), a bispecific antibody targeting HER2-expressing tumors; zanidatamab for the treatment of neoadjuvant populations, breast cancer, and other HER2-expressing cancers; Pasritamig, a bispecific T cell engager targeting human kallikrein 2 for the treatment monotherapy and castration resistant prostate cancer; ZW191, a clinical- antibody-drug conjugates (ADC) that targets folate receptor alpha expressing tumors, including ovarian, endometrial, and non-small cell lung cancers; ZW251, a clinical-stage ADC molecule for the treatment of glypican 3 expressing hepatocellular carcinoma; ZW220, an ADC that targets NaPi2b-expressing NSCLC and ovarian cancer; ZW209, a novel TriTCE targeting Delta-like ligand 3 -expressing tumor cells for the treatment of solid tumors; and ZW1528, a bispecific molecule to treat chronic obstructive pulmonary disease. It has strategic partnerships and collaborations with Jazz Pharmaceuticals plc; Bristol- Myers Squibb company; Celgene Alpine Investment Co. LLC; GlaxoSmithKline Intellectual Property Development Limited; Daiichi Sankyo Co., Ltd.; Merck Sharp & Dohme Research GmbH; and Janssen Biotech, Inc. Zymeworks Inc. was incorporated in 2003 and is based in Middletown, Delaware.
Why Investors Should Care
Revenue has grown at a 28.4% CAGR over the past five years.
Carries low leverage with a debt-to-equity ratio of 0.20.
Recent Developments
- Dec 2025 Revenue of $105.97M (+38.9% YoY); net profit $-81.13M.
- Trailing 12 Months Year-on-year growth — revenue -90.6%.
- 5-Year Trend Long-term compounding — revenue CAGR 28.4%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 28.43% |
| 1 Year: | -90.60% |
Stock Price Performance
| 1 Year: | +102.44% |
| 6 Months: | +0.43% |
| 3 Months: | +22.70% |
| 1 Month: | +5.26% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- RSI (14)59.63 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Compounding revenue at 28.4% over 5 years.
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
No notable concerns flagged.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | ZYME Zymeworks Inc. R2KR3KPHARMA | 28.22 | -14.47 | $2.00B | 0.00% | -30.42% | -72.31% | 28.43% | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,273.46 | 42.83 | $1.14T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 263.81 | 30.60 | $635.76B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 285.64 | 80.69 | $504.76B | 2.54% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 418.09 | 26.85 | $375.28B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 6 | MRK Merck & Co., Inc. SPXR3KPHARMA | 145.27 | 116.22 | $358.41B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 7 | NVS Novartis AG PHARMA | 151.12 | 22.83 | $287.24B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 171.49 | 25.63 | $265.96B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 673.82 | 36.30 | $249.14B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | 4.39M | 1.92M | 5.44M | 2.63M | 35.58M | 7.00M | 16.51M | 10.03M | 19.24M | 16.00M | - | 27.11M | 48.73M | 27.61M | 2.52M | 2.41M | 4.59M |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | 52.74M | 49.35M | 49.68M | 46.63M | 49.56M | - |
| Operating Income | - | - | -60.96M | -72.69M | -65.82M | -50.36M | -27.28M | -54.11M | -33.24M | -37.80M | -42.89M | -34.20M | - | -25.63M | -623.00K | -22.06M | -44.12M | -47.15M | -42.18M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | -18.84M | 2.59M | -19.48M | -42.11M | -41.44M | - |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | 0 | - | - | - | 2.07M | - |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | -22.14M | 2.13M | -18.27M | -41.48M | -46.35M | - |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | 496.00K | -186.00K | 1.34M | -270.00K | -2.19M | - |
| Net Income | -44.59M | -67.52M | -60.58M | -72.62M | -64.62M | -47.85M | -24.35M | -51.15M | -28.69M | -31.65M | -37.69M | -29.85M | - | -22.64M | 2.32M | -19.60M | -41.21M | -44.16M | -45.02M |
| Diluted EPS | - | - | -1.25 | -1.19 | -0.97 | -0.72 | -0.37 | -0.76 | -0.41 | -0.42 | -0.49 | -0.39 | - | -0.30 | 0.03 | -0.26 | -0.55 | -0.59 | -0.62 |
| R&D Expense | - | - | 49.89M | 62.51M | 56.02M | 37.10M | 45.91M | 39.41M | 32.77M | 32.04M | - | - | - | - | - | - | - | - | - |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Revenue | 38.95M | - | 412.48M | 76.01M | 76.30M | 105.97M |
| Cost of Revenue | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - |
| Operating Expenses | - | - | 282.00M | 214.02M | 196.12M | 198.50M |
| Operating Income | -187.47M | - | 130.49M | -138.01M | -119.82M | -92.53M |
| EBITDA | - | - | 142.49M | -120.70M | -108.62M | -81.42M |
| Interest Expense | - | - | - | - | - | - |
| Pretax Income | - | - | 135.23M | -119.24M | -116.61M | -79.75M |
| Tax Provision | - | - | 10.89M | -568.00K | 6.08M | 1.38M |
| Net Income | -180.55M | - | 124.34M | -118.67M | -122.69M | -81.13M |
| Diluted EPS | -3.58 | - | 1.90 | -1.72 | -1.62 | -1.08 |
| R&D Expense | 171.20M | 199.75M | 208.60M | 143.62M | - | - |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Total Assets | - | - | - | 648.73M | 580.88M | 463.09M | 346.53M |
| Current Assets | - | - | - | 544.71M | 412.93M | 300.45M | 248.77M |
| Cash & Equivalents | - | - | - | 400.91M | 157.56M | 66.10M | 41.16M |
| Inventory | - | - | - | - | - | - | - |
| Receivables | - | - | - | 33.40M | 19.48M | 55.81M | 4.64M |
| Total Liabilities | - | - | - | 155.77M | 116.07M | 124.32M | 78.03M |
| Current Liabilities | - | - | - | 95.62M | 55.76M | 88.29M | 42.32M |
| Long Term Debt | - | - | - | - | - | - | - |
| Total Debt | - | - | - | 28.11M | 26.72M | 18.51M | 18.27M |
| Total Equity | 245.68M | 409.92M | - | 492.96M | 464.81M | 338.77M | 268.50M |
| Shares Outstanding | - | - | - | 63.06M | 70.12M | 68.96M | 75.19M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -151.40M | - | 144.11M | -118.32M | -110.06M | -33.01M |
| Investing Cash Flow | -43.44M | - | -53.85M | -207.25M | 38.76M | 26.66M |
| Financing Cash Flow | 308.98M | - | 108.58M | 81.87M | -20.44M | -18.56M |
| Capital Expenditure | -4.31M | - | -13.12M | -4.08M | -3.07M | -2.35M |
| Free Cash Flow | -155.71M | - | 130.98M | -122.40M | -113.12M | -35.36M |
| Net Change in Cash | - | - | 198.84M | -243.71M | -91.74M | -24.90M |
| Share Buybacks | - | - | 0 | 0 | 30.05M | 41.70M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - |
| Operating Margin % | -481.3% | - | 31.6% | -181.6% | -157.0% | -87.3% |
| Net Margin % | -463.5% | - | 30.1% | -156.1% | -160.8% | -76.6% |
| ROE % | -44.0% | - | 25.2% | -25.5% | -36.2% | -30.2% |
| ROCE % | - | - | 23.6% | -26.3% | -32.0% | -30.4% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | EcoR1 Capital, LLC | 36.46% | 22.97M | $592.41M |
| 2 | Rubric Capital Management LP | 11.11% | 7.00M | $180.53M |
| 3 | Blackrock Inc. | 6.75% | 4.25M | $109.63M |
| 4 | Perceptive Advisors Llc | 6.64% | 4.18M | $107.88M |
| 5 | BVF Inc. | 5.79% | 3.65M | $94.11M |
| 6 | Morgan Stanley | 3.54% | 2.23M | $57.54M |
| 7 | BNP Paribas Asset Management Holding S.A. | 2.83% | 1.78M | $45.93M |
| 8 | Vanguard Capital Management LLC | 2.47% | 1.56M | $40.21M |
| 9 | Assenagon Asset Management S.A. | 1.99% | 1.25M | $32.29M |
| 10 | Nextech Invest, Ltd. | 1.77% | 1.11M | $28.73M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for ZYME
ZYME — Frequently Asked Questions
What is the current share price of Zymeworks Inc. (ZYME)?
As of 2026-10-23 16:27 PDT, Zymeworks Inc. (ZYME) trades at $28.22 on NasdaqGS. Its 52-week range is $13.94 to $31.05.
What is the market capitalisation of ZYME?
Zymeworks Inc. (ZYME) has a market capitalisation of $2.00B on NasdaqGS.
What is the P/E ratio of ZYME?
ZYME trades at a trailing price-to-earnings (P/E) ratio of -14.47. The industry average P/E is 25.45. Its price-to-book (P/B) ratio is 23.62.
What is the return on equity (ROE) of ZYME?
ZYME has a return on equity (ROE) of -72.31%. Its return on capital employed (ROCE) is -30.42%.
Is ZYME a good stock to buy?
This page provides a data-driven analysis of Zymeworks Inc. (ZYME), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.